<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04099732</url>
  </required_header>
  <id_info>
    <org_study_id>1402-0009</org_study_id>
    <secondary_id>2019-002763-10</secondary_id>
    <nct_id>NCT04099732</nct_id>
  </id_info>
  <brief_title>A Study in Healthy Men to Test the Influence of BI 1358894 on the Amount of the Medicines Rosuvastatin and Dabigatran in the Blood</brief_title>
  <official_title>Relative Bioavailability of Rosuvastatin (Part 1) and Dabigatran (Part 2) Given Alone and Together With BI 1358894 in Healthy Male Subjects (Open, Single-dose, Fixed Sequence, Two-period Crossover Design in Each Trial Part)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this trial is to investigate the relative bioavailability of
      rosuvastatin (Reference 1, Part 1) and dabigatran (Reference 2, Part 2) given alone and
      together with BI 1358894 (Test 1, Test 2) following oral administration.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 7, 2019</start_date>
  <completion_date type="Actual">December 10, 2019</completion_date>
  <primary_completion_date type="Actual">December 10, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: AUC0-∞ (area under the concentration-time curve of the analyte (rosuvastatin) in plasma over the time interval from 0 extrapolated to infinity)</measure>
    <time_frame>Up to 96 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Cmax (maximum measured concentration of the analyte (rosuvastatin) in plasma)</measure>
    <time_frame>Up to 96 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: AUC0-∞ (area under the concentration-time curve of the analyte (dabigatran) in plasma over the time interval from 0 extrapolated to infinity)</measure>
    <time_frame>Up to 72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Cmax (maximum measured concentration of the analyte (dabigatran) in plasma)</measure>
    <time_frame>Up to 72 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1: AUC0-tz (area under the concentration-time curve of the analyte (rosuvastatin) in plasma over the time interval from 0 to the last quantifiable data point)</measure>
    <time_frame>Up to 96 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: AUC0-tz (area under the concentration-time curve of the analyte (dabigatran) in plasma over the time interval from 0 to the last quantifiable data point)</measure>
    <time_frame>Up to 72 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Part 1: Reference 1 followed by Test 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Reference 1 - Rosuvastatin. Test 1 - Rosuvastatin + BI 1358894</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Reference 2 followed by Test 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Reference 2 - Dabigatran etexilate. Test 2 - Dabigatran etexilate + BI 1358894</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>Tablet</description>
    <arm_group_label>Part 1: Reference 1 followed by Test 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 1358894</intervention_name>
    <description>Tablet</description>
    <arm_group_label>Part 1: Reference 1 followed by Test 1</arm_group_label>
    <arm_group_label>Part 2: Reference 2 followed by Test 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Dabigatran etexilate</intervention_name>
    <description>Capsule</description>
    <arm_group_label>Part 2: Reference 2 followed by Test 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Healthy male subjects according to the assessment of the investigator, as based on a
             complete medical history including a physical examination, vital signs (Blood pressure
             (BP), Pulse rate (PR)), 12-lead Electrocardiogram (ECG), and clinical laboratory tests

          -  Age of 18 to 55 years (inclusive)

          -  Body mass index (BMI) of 18.5 to 29.9 kg/m^2 (inclusive)

          -  Signed and dated written informed consent prior to admission to the study, in
             accordance with Good Clinical Practice (GCP) and local legislation

        Exclusion criteria:

          -  Any finding in the medical examination (including Blood pressure (BP), Pulse rate (PR)
             or Electrocardiogram (ECG)) deviating from normal and assessed as clinically relevant
             by the investigator

          -  Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg,
             diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the
             range of 45 to 90 bpm

          -  Any laboratory value outside the reference range that the investigator considers to be
             of clinical relevance (including positive or missing faecal occult blood test in Part
             2, retest allowed)

          -  Any evidence of a concomitant disease assessed as clinically relevant by the
             investigator

          -  Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological or hormonal disorders

          -  Cholecystectomy or other surgery of the gastrointestinal tract that could interfere
             with the pharmacokinetics of the trial medication (except appendectomy or simple
             hernia repair)

          -  Diseases of the central nervous system (including but not limited to any kind of
             seizures or stroke), and other relevant neurological or psychiatric disorders

          -  History of relevant orthostatic hypotension, fainting spells, or blackouts

          -  Chronic or relevant acute infections

          -  History of relevant allergy or hypersensitivity (including allergy to the trial
             medication or its excipients)

          -  Use of drugs within 30 days of planned administration of trial medication that might
             reasonably influence the results of the trial (including drugs that cause QT/QTc
             interval prolongation)

          -  Intake of an investigational drug in another clinical trial within 60 days of planned
             administration of investigational drug in the current trial, or concurrent
             participation in another clinical trial in which investigational drug is administered

          -  Smoker (more than 10 cigarettes or 3 cigars or 3 pipes per day)

          -  Inability to refrain from smoking on specified trial days

          -  Alcohol abuse (consumption of more than 24 g per day)

          -  Drug abuse or positive drug screening

          -  Blood donation of more than 100 mL within 30 days of planned administration of trial
             medication or intended blood donation during the trial

          -  Intention to perform excessive physical activities within one week prior to the
             administration of trial medication or during the trial

          -  Inability to comply with the dietary regimen of the trial site

          -  A marked prolongation of QTc interval (such as QTc intervals that are repeatedly
             greater than 450 ms) or any other relevant ECG finding at screening

          -  A history of additional risk factors for Torsade de Pointes (such as heart failure,
             hypokalaemia, or family history of Long QT Syndrome)

          -  Subject is assessed as unsuitable for inclusion by the investigator, for instance,
             because the subject is not considered able to understand and comply with study
             requirements, or has a condition that would not allow safe participation in the study

          -  Male subjects with women of child bearing potential (WOCBP) partner who are unwilling
             to use male contraception (condom or sexual abstinence) from time point of
             administration of trial medication until 30 days thereafter. Sperm donation is not
             allowed from the time point of drug administration until 30 days thereafter.

          -  Known hypersensitivity to rosuvastatin or dabigatran

          -  Active liver disease including elevations of serum transaminases exceeding 2 times the
             upper limit of normal

          -  Moderate or severe renal impairment (creatinine clearance &lt; 60 ml/min based on
             estimated Glomerular Filtration Rate (GFR) according to Chronic Kidney Disease
             Epidemiology Collaboration (CKD-EPI) formula

          -  Known myopathy

          -  Concomitant treatment with systemic cyclosporine, ketoconazole, itraconazole and
             dronedarone or use of fibrates

          -  Hypothyroidism

          -  Personal or family history of hereditary muscular disorders

          -  History of muscular toxicity with another statin or fibrate

          -  Asian ancestry

          -  Known active bleeding

          -  Concomitant treatment with other anticoagulants (e.g. unfractionated heparin, low
             molecular weight heparins, heparin derivatives, oral anticoagulants)

          -  Prosthetic heart valves

          -  Subjects who in the investigator's judgement are perceived as having an increased risk
             of bleeding, for example because of: current or recent gastrointestinal ulceration,
             presence of malignant neoplasms, recent brain or spinal injury, recent brain / spinal/
             ophthalmic surgery, recent intracranial hemorrhage, known or suspected oesophageal
             varices, arteriovenous malformations, vascular aneurysms, major intraspinal or
             intracerebral vascular abnormalities
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Humanpharmakologisches Zentrum Biberach</name>
      <address>
        <city>Biberach</city>
        <zip>88397</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>September 20, 2019</study_first_submitted>
  <study_first_submitted_qc>September 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2019</study_first_posted>
  <last_update_submitted>January 9, 2020</last_update_submitted>
  <last_update_submitted_qc>January 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dabigatran</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non‐interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions:
1. studies in products where Boehringer Ingelheim is not the license holder; 2. studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; 3. studies conducted in a single center or targeting rare diseases (because of limitations with anonymization). For more details refer to: http://trials.boehringer‐ingelheim.com/</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

